Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.11B.
ENTERPRISE VALUE (EV)
$2.11B
NewAmsterdam Pharma Company N.V.
Market Cap
$2.60B
Enterprise Value (EV)
$2.11B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.60B | $2.11B |
| Beam Therapeutics Inc. (BEAM)vs › | $2.61B | $2.64B |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | N/A |
| Neogen Corporation (NEOG)vs › | $2.67B | $3.28B |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.68B | $4.09B |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | $5.09B |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | $2.66B |
| Precigen, Inc. (PGEN)vs › | $2.72B | $2.80B |
| Disc Medicine, Inc. (IRON)vs › | $2.45B | $2.41B |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.44B | $1.96B |
Market Cap
$2.60B
Total Debt
$202000.00
Cash
$490.00M
Enterprise Value
$2.11B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
